Prediction of novel target genes and pathways involved in tall cell variant papillary thyroid carcinoma

Xia, Fada; Jiang, Bo; Chen, Yong; Du, Xin; Yao, Peng; Wang, Wenlong; Wang, Zhuolu; Li, Xinying

doi:10.1097/md.0000000000013802

Cited by 15 publications

(11 citation statements)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the second most abundant cation in the cell, Mg 2+ acts as a cofactor of more than 300 enzymatic reactions, involving energy metabolism and protein and nucleic acid synthesis 25,26. Further, Mg 2+ participates in the process of synthesis and/or secretion of PTH by regulating the activity of the calcium sensitive receptor (CaSR) signal axis, which affects the sensitivity of target organs to PTH and participates in the synthesis of 1,25(OH) 2 D 3 25,27,28. Therefore, to some extent, hypomagnesemia or a decrease in serum Mg increases hypocalcemia risk after thyroidectomy.…”

Section: Discussionmentioning

confidence: 99%

<p>Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy</p>

Wang¹,

Meng²,

Ouyang³

et al. 2019

CMAR

Self Cite

View full text Add to dashboard Cite

Background This study was designed to investigate the impact of serum magnesium (Mg) levels on hypocalcemia after thyroidectomy. Patients and methods In total, 242 patients with differentiated thyroid cancer were retrospectively analyzed. Results Multivariate regression analysis showed hypomagnesemia was an independent risk factor for hypocalcemia ( P <0.001). While Mg in low levels (0.66 mmol/L ≤ Po-Mg ≤0.74 mmol/L) increased the risk of hypocalcemia, postoperative serum Ca (Po-Ca) levels were significantly lower in patients with hypomagnesemia than in patients with normomagnesemia ( P =0.01), and the former patients suffered significant decreases in serum Ca ( P =0.02). Compared to patients with a mild decline of serum Mg after surgery (ΔMg <0.17), serum Ca decline significantly increased ( P <0.001) in patients with a severe decline of serum Mg (ΔMg ≥0.17), while the change in amounts of parathyroid hormone (PTH) after surgery was similar between the two groups ( P >0.05). In patients with normal Po-Ca levels, hypomagnesemia increased the risk of symptoms related to hypocalcemia by 4.478 times (OR =5.478, 95% CI 1.724–17.403). Conclusion Hypomagnesemia, or even a low serum Mg level within the normal range, can increase the risk of hypocalcemia. After excluding the potential effects of PTH on serum magnesium and calcium, serum Mg reduction is one of the most important factors that influences postoperative serum Ca reduction. What’s more, hypomagnesemia is closely linked with symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy</p>

Wang¹,

Meng²,

Ouyang³

et al. 2019

CMAR

Self Cite

View full text Add to dashboard Cite

show abstract

“…The identified differentially expressed genes were inputted into the STRING database to obtain the protein-protein interaction network ( http://string.embl.de/ ). Subnetwork models were selected using the plugin molecular complex detection (MCODE) application in Cytoscape, with the following criteria: degree cutoff = 2, node score cutoff = 0.2, k-core = 2, and max depth = 100 [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Overexpression of CRABP2 inhibits dexamethasone-induced apoptosis in human osteoblast cells

Zhang

Sun

et al. 2021

J Orthop Surg Res

View full text Add to dashboard Cite

Background The purpose of the current study was to explore the role and underlying mechanism of cellular retinoic acid binding protein 2 (CRABP2) in dexamethasone (DEX)-induced apoptosis in human osteoblast cells. Methods GSE10311 was downloaded from the Gene Expression Omnibus (GEO) database to identify the differentially expressed genes (DEGs) by the limma/R package. Primary human osteoblast was isolated and treated with different concentration of DEX (0, 10-8, 10-7, 10-6, 10-5, and 10-4 mol/L), and cell viability and flow cytometry were used to detect cell proliferation and apoptosis. A CRABP2 overexpression plasmid (oe-CRABP2) was used to overexpress CRABP2, and western blotting was conducted to detect protein expression. Results We found that CRABP2 was downregulated in the DEX-treated group. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses indicated that DEGs were associated with PI3K/Akt signaling pathway. DEX downregulated CRABP2 gene and protein expression, inhibited viability, and induced human osteoblast apoptosis. Overexpression of CRABP2 reversed DEX-induced apoptosis in human osteoblast. Moreover, overexpression of CRABP2 delayed the progression of DEX-induced osteonecrosis of the femoral head (ONFH) animal model. Conclusion In conclusion, CRABP2 is effective at inhibiting DEX-induced human osteoblast apoptosis and delayed ONFH progression.

show abstract

“…The MAPK pathway is a signal transduction cascade driven by phosphorylation that leads to intracellular responses such as cell proliferation [15]. Thus, BRAF acts as a protooncogene and has an important function in cell growth, differentiation and apoptosis, with its point mutations that have been noted in various human cancers [16]. In PTC, a common mutation in the BRAF gene comprises a missense mutation that consists of a thymine-to-adenine transversion at nucleotide 1799 (T1799A) within exon 15, which leads to the substitution of a valine residue for a glutamate one at position 600 of the protein (V600E), with consequent gain of function, constitutive activation of MAPK pathway, i.e.…”

Section: Molecular Pathophysiologymentioning

confidence: 99%

PET/CT in thyroid cancer — the importance of BRAF mutations

2020

View full text Add to dashboard Cite

Thyroid cancer (TC) represents less than 1% of all newly diagnosed malignancies. In some selected cases, with a high clinical suspicion for disease but negative I-131 scan, positron emission tomography/computed tomography (PET) with F-18-Fluorodeoxyglucose (FDG) could be helpful in the detection of disease and the definition of its extent. FDG PET/CT, better if performed after TSH stimulation analogously to patient preparation done for radioiodine scintigraphy, could be useful mainly in the detection of metastatic and recurrent disease since the uptake and diagnostic sensitivity of FDG are increased by TSH stimulation.Recently, the role of oncogenic mutations in the tumorigenesis of TCs has become clearer. Among such mutations, BRAF V600E represents the most common genetic alteration. Mutated BRAF may define a more aggressive papillary carcinoma with poorer prognosis and therefore its analysis has been extensively studied as a rule-in test for thyroid carcinoma.In this paper, we try to outline the possible role of FDG PET/CT in the management of patients with TC and positive BRAF mutations and the impact that it could have on their therapeutic algorithm, in terms of thyroidectomy and radioactive iodine (RAI) therapy.

show abstract

Prediction of novel target genes and pathways involved in tall cell variant papillary thyroid carcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 15 publications

References 40 publications

<p>Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy</p>

<p>Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy</p>

Overexpression of CRABP2 inhibits dexamethasone-induced apoptosis in human osteoblast cells

PET/CT in thyroid cancer — the importance of BRAF mutations

Contact Info

Product

Resources

About